We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Autosomal Dominant Disorder Confirmed by Biomarker Assay

By LabMedica International staff writers
Posted on 06 Feb 2012
Print article
The erythrocyte glucose-uptake assay has been used to confirm the diagnosis of glucose transporter type 1 deficiency syndrome (Glut1-DS).

The disease is diagnosed with cerebrospinal fluid (CSF) glucose values of less than 2.2 mmol/L, or lowered CSF/plasma glucose ratio of less than 0.4, and the erythrocyte 3-O-methyl-d-glucose uptake assay (3-OMG).

Scientists at Columbia University (New York, NY, USA) studied 109 suspected cases of Glut-1 DS, all who had a consistent clinical picture and a low CSF glucose concentration (hypoglycorrhachia). To confirm the diagnosis of Glut1 DS, blood samples from both patients and parents were analyzed using the erythrocyte 3-OMG uptake assay. The erythrocytes are radioactively labeled and measured on a scintillation counter.

Copy number analysis was performed via single nucleotide polymorphism (SNP) oligonucleotide microarray analysis (SOMA) using the Affymetrix Genome Wide Human SNP Array 6.0 (Santa Clara, CA, USA), which includes over 906,600 SNPs and more than 946,000 probes for the detection of copy number variation. A multiplex ligation-dependent probe amplification (MLPA) kit (MRC-Holland; Amsterdam, Netherlands) was used to screen eight patients with decreased 3-OMG uptake without identified sequence based mutations or deletions using SOMA. .

The uptake assay was decreased in 74 cases (group 1) and normal in 35 cases (group 2). The disease-causing mutations were identified in 70 group 1 patients (95%) and only one in group 2 patients (3%). The cut-off for an abnormally low uptake value was increased from 60% to 74% with a corresponding sensitivity of 99% and specificity of 100%. The correlation between the uptake values for the time-curve and the kinetic concentration curve were strongly positive. There was a significant correlation between the mean erythrocyte 3-OMG uptake and clinical severity.

The authors concluded that the erythrocyte glucose-uptake assay, when abnormal, essentially confirms the clinical suspicion of Glut1 DS. Furthermore, the degree of uptake abnormality correlates with glucose transport functional activity and has implications regarding clinical severity and prognosis. Glut1 deficiency syndrome is characterized classically by infantile onset seizures, delayed neurological development, disorders of movement, and acquired microcephaly. The study was published in December 2011, in the Annals of Neurology.

Related Links:

Columbia University
Affymetrix
MRC-Holland


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.